SARS-CoV-2 (COVID-19) Spike Q493R G496S Q498R N501Y Y505H Antibody (Omicron)

Back Contact us
ProSci
Product Code: PSI-9805
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9805-0.02mg0.02mg£150.00
Quantity:
PSI-9805-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: SARS-CoV-2
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence (IF)
  • Neutralisation
  • Western Blot (WB)
Storage:
SARS-CoV-2 Omicron Variant Spike antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 5
<strong>Figure 1 Immunofluorescence Validation of Spike RBD in the Nasal Swab Sample of Omicron Variant COVID-19 Patient. </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed patient nasal swab sample labeling spike RBD with 9805 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
2 / 5
<strong>Figure 2 Neutralization Assay of Omicron Variant Pseudovirus by SARS-CoV-2 Omicron Variant Spike RBD Antibody </strong><br> Neutralization antibodies: Anti-SARS-CoV-2 Spike RBD antibodies, 9805, dilution: 0.3 ? 30,000 ng/mL. Pseudovirus: SARS-CoV-2 Omicron Spike Pseudovirus, 95-201. Infected Cells: ACE2-overexpressing 293T cells Diluted antibody was incubated with Omicron pseudovirus at 37 ˚C for 1 hr. ACE2-overexpressing 293T cells were added in each well and incubated at 37 ˚C for 48 hrs. Luminescence reporter reagent was added in each well and the final results were read with the luminescence plate reader. Percent inhibition is calculated based on the RLU value.
3 / 5
<strong>Figure 3 SARS-Cov-2 Omicron Variant Spike Antibodies Specifically Detect Omicron Variant Spike S1 Protein in an ELISA </strong><br> Coating Antigen: SARS-CoV-2 spike S1 proteins of WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight. Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 1 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr.
4 / 5
<strong>Figure 4 SARS-Cov-2 Omicron Variant Spike Antibodies Specifically Detect Omicron Variant Spike RBD Protein in an ELISA </strong><br> Coating Antigen: SARS-CoV-2 spike RBD proteins of WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight. Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 1 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr.
5 / 5
<strong>Figure 5 WB Validation of of Omicron Variant Spike Antibodies with SARS-CoV-2 Variant Spike S1 Proteins </strong><br> Loading: 30 ng of SARS-CoV-2 spike S1 proteins, including WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 2 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr. <strong>SARS-CoV-2 Omicron Variant Spike antibody (9805) specifically detects Omicron variant spike S1 protein (95-129), but not spike S1 protein of WT (10-300) and all other variants. </strong>
❮❯

<strong>Figure 1 Immunofluorescence Validation of Spike RBD in the Nasal Swab Sample of Omicron Variant COVID-19 Patient. </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed patient nasal swab sample labeling spike RBD with 9805 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
<strong>Figure 2 Neutralization Assay of Omicron Variant Pseudovirus by SARS-CoV-2 Omicron Variant Spike RBD Antibody </strong><br> Neutralization antibodies: Anti-SARS-CoV-2 Spike RBD antibodies, 9805, dilution: 0.3 ? 30,000 ng/mL. Pseudovirus: SARS-CoV-2 Omicron Spike Pseudovirus, 95-201. Infected Cells: ACE2-overexpressing 293T cells Diluted antibody was incubated with Omicron pseudovirus at 37 ˚C for 1 hr. ACE2-overexpressing 293T cells were added in each well and incubated at 37 ˚C for 48 hrs. Luminescence reporter reagent was added in each well and the final results were read with the luminescence plate reader. Percent inhibition is calculated based on the RLU value.
<strong>Figure 3 SARS-Cov-2 Omicron Variant Spike Antibodies Specifically Detect Omicron Variant Spike S1 Protein in an ELISA </strong><br> Coating Antigen: SARS-CoV-2 spike S1 proteins of WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight. Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 1 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr.
<strong>Figure 4 SARS-Cov-2 Omicron Variant Spike Antibodies Specifically Detect Omicron Variant Spike RBD Protein in an ELISA </strong><br> Coating Antigen: SARS-CoV-2 spike RBD proteins of WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight. Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 1 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr.
<strong>Figure 5 WB Validation of of Omicron Variant Spike Antibodies with SARS-CoV-2 Variant Spike S1 Proteins </strong><br> Loading: 30 ng of SARS-CoV-2 spike S1 proteins, including WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), Detection Antibodies: SARS-CoV-2 Omicron Variant Spike antibody, 9805, 2 μg/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubated at RT for 1 hr. <strong>SARS-CoV-2 Omicron Variant Spike antibody (9805) specifically detects Omicron variant spike S1 protein (95-129), but not spike S1 protein of WT (10-300) and all other variants. </strong>

Documents

Further Information

Additional Names:
SARS-CoV-2 Omicron Variant Spike antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein, Omicron Variant
Application Note:
WB: 2 μg/mL; IF: 20 μg/mL; Neut: 0.1-10 μg/mL

Antibody validated: Western Blot and Immunofluorescence staining in human samples; Neutralization in Omicron pseudovirus samples. Anti-SARS-CoV-2 Omicron variant Spike antibody specifically detects Spike S1 protein of Omicron Variant (B.1.1.529), but not WT and other variant by ELISA and WB. All other applications and species not yet tested.
Background:
SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, in which the receptor binding domain (RBD) protein contains 15 mutations. Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent
Background References:
  • Gowrisankar et al. European Physical Journal Plus, 2022, 137(1), 100.
  • Zhang et al. PNAS of U.S.A. 2021, 118(47):e2109905118.
  • Cameroni et al. Nature 2021.
  • Rossler et al. NEJM 2022.
  • Muik et al. Science 2022.
Buffer:
Anti-SARS-CoV-2 Omicron Variant Spike antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (55%)
Immunogen:
Anti-SARS-CoV-2 Spike Q493R G496S Q498R N501Y Y505H (Omicron) antibody(9805) was raised against a peptide corresponding to 20 amino acids in the receptor binding domain of SARS-CoV-2 Omicron variant (B.1.1.529) Spike protein.

The immunogen is located within 480-530 amino acids of SARS-CoV-2 Omicron variant (B.1.1.529) Spike protein.
NCBI Gene ID #:
43740568
NCBI Official Name:
surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
Severe acute respiratory syndrome coronavirus 2
Physical State:
Liquid
Protein Accession #:
QHD43416
Protein GI Number:
1791269090
Purification:
Anti-SARS-CoV-2 Omicron Variant Spike antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease, COVID-19
SPECIFICITY:
It can only detect SARS-CoV-2 Omicron Variant (B.1.1.529) Spike protein and does not cross-react with the spike proteins of other variants.
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.